Új vizsgálatok, publikációk, preprintek és pályázatok ezen a célponton, hónapról hónapra.
Vizsgálat
Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML
2027. jan. 31.· PHASE1 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations
2026. dec. 31.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation
2026. dec. 1.· PHASE1_PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
FILOCLL017 - NEVOTAL : Nemtabrutinib in addition to Venetoclax-Obinutuzumab in chronic lymphocytic leukemia (CLL) / small lymphocytic leukemia (SLL) patients with TP53 ALterations
2026. dec. 1.· PHASE2 · NOT_YET_RECRUITING· CTIS
Vizsgálat
ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDS
2026. nov. 30.· PHASE1 · NOT_YET_RECRUITING· CTGOV
Publikáció
[Dedifferentiated solitary fibrous tumor of the kidney with RB1/p16 pathway abnormalities and TP53 mutation: report of a case].
2026. nov. 8.· Zhonghua bing li xue za zhi = Chinese journal of pathology· PUBMED
Publikáció
NRF2 and mutant p53 separately regulate redox balance in esophageal squamous cell carcinoma through metabolic reprogramming.
2026. nov. 6.· Cancer biology & therapy· PUBMED
Publikáció
Toxoplasma gondii GRA16-induced apoptosis in KRAS-mutant colorectal cancer cells is linked to coordinated p53 and PP2A-B55 signaling.
2026. nov. 6.· Parasites, hosts and diseases· PUBMED
Publikáció
Sirt1 Modulates p53‑Acetylation‑Dependent Yy2‑Elf‑1‑Associated NLRP3‑Relevant Signaling in CUMS‑Evoked Aggravated Alzheimer's Disease‑Related Phenotypes.
2026. nov. 5.· Brain research bulletin· PUBMED
Publikáció
Statement of Retraction: DEP domain containing 1B (DEPDC1B) exerts the tumor promoter in hepatocellular carcinoma through activating p53 signaling pathway via kinesin family member 23 (KIF23).
2026. nov. 5.· Bioengineered· PUBMED
Publikáció
Statement of Retraction: Long non-coding RNA p53 upregulated regulator of p53 levels (PURPL) promotes the development of gastric cancer.
2026. nov. 5.· Bioengineered· PUBMED
Publikáció
Circulating Tumor DNA Profiling Across Phase II/III Ewing Sarcoma Trials Identifies High-Risk Patients With TP53, STAG2, and CDKN2A Alterations.
2026. nov. 4.· Journal of clinical oncology : official journal of the American Society of Clinical Oncology· PUBMED
Publikáció
Aflatoxin B1 (AFB1) Accelerates the Pathological Process of Hepatic Aging by Hijacking the Aryl Hydrocarbon Receptor (AHR) Signaling Pathway.
2026. nov. 4.· Journal of agricultural and food chemistry· PUBMED
Publikáció
Crocin attenuates dopaminergic neuronal injury in 6-OHDA-induced PD rats: Associations with mitochondrial protection and p38/p53 signaling.
2026. nov. 4.· Brain research bulletin· PUBMED
Publikáció
Omega-3 DHA Targets P53-Mutant CRC Stem-like Cells via Membrane Disruption, Modulation of Differential Marker Genes, and Suppression of Self-Renewal Capacity.
2026. nov. 4.· International journal of toxicology· PUBMED
Publikáció
Impacts of mutation accumulation and order on tumor initiation revealed by engineered murine colorectal cancer organoids.
2026. nov. 3.· eLife· PUBMED
Publikáció
A Selective CK1α Degrader Targets Acute Myeloid Leukemia and Spares Normal Hematopoietic Cells.
2026. nov. 3.· Cancer research· PUBMED
Publikáció
TP53-Mutated Preneoplastic Colonies, Adaptive Immune Response, and Risk for Lung Cancer and COPD.
2026. nov. 2.· Cancer prevention research (Philadelphia, Pa.)· PUBMED
Vizsgálat
Arsenic Trioxide to Prevent Relapse in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome
2026. nov. 1.· PHASE1 · NOT_YET_RECRUITING· CTGOV
Publikáció
Non-Small Cell Lung Carcinoma With Bilayered Architecture and TP53 Alteration: A Diagnostic Pitfall and a Potential Distinct Entity.
2026. nov. 1.· Thoracic cancer· PUBMED
Publikáció
Short-Course Selinexor and Decitabine With Homoharringtonine-Based Chemotherapy for Pretransplant Cytoreduction in TP53-Altered Complex-Karyotype Myeloid Neoplasms.
2026. nov. 1.· Hematological oncology· PUBMED
Publikáció
ASO Visual Abstract: KRAS and TP53 Circulating Tumor DNA are Prognostic in Localized Pancreatic Cancer.
2026. nov. 1.· Annals of surgical oncology· PUBMED
Publikáció
Diagnostic and prognostic significance of p16, p53, and PD-L1 expression in cervical lesions: A combined immunohistochemical, histopathological, and radiological correlation study.
2026. okt. 30.· Indian journal of pathology & microbiology· PUBMED
Publikáció
Comparative immunohistochemical analysis of survivin, p53, and Ki-67 expression in cervical squamous intraepithelial lesions and squamous cell carcinoma.
2026. okt. 30.· Indian journal of pathology & microbiology· PUBMED
Publikáció
TP53 dysregulation in Wilms tumor: an integrative clinico-genomic analysis and its prognostic implications.
2026. okt. 30.· Molecular genetics and genomics : MGG· PUBMED
Publikáció
Resveratrol partially restores the expression of the clock genes Per1 and Bmal1 in the suprachiasmatic nucleus of scopolamine-induced Alzheimer's rat model.
2026. okt. 29.· Experimental brain research· PUBMED
Publikáció
ATR inhibitors and gemcitabine synergize to induce cell death in TP53-mutant, ATRX-wildtype uterine leiomyosarcoma.
2026. okt. 29.· Molecular cancer therapeutics· PUBMED
Publikáció
Editorial Expression of Concern: Cell death by the quinoxaline dioxide DCQ in human colon cancer cells is enhanced under hypoxia and is independent of p53 and p21.
2026. okt. 28.· Radiation oncology (London, England)· PUBMED
Publikáció
USP25 promotes ferroptosis in diabetic retinopathy by deubiquitinating p53 and suppressing the GPX4/SLC7A11 axis.
2026. okt. 27.· Journal of diabetes investigation· PUBMED
Publikáció
USP22-mediated phagocytic evasion promotes immune escape in TP53-inactivated hepatocellular carcinoma.
2026. okt. 27.· Clinical and molecular hepatology· PUBMED